drugset / Trial / NCT04561063

COVID-19 Prophylaxis South Africa (COVER HCW)

NCT04561063

Phase 2 Completed 1950 enrolled University of Witwatersrand, South Africa
RandomizedParallel-groupOpen-labelPrevention

Summary

This is a randomised, multi-center, open label, adaptive, exploratory trial to assess the efficacy of two different drug regimens in terms of preventing symptomatic COVID-19 disease in healthcare workers at high risk of exposure to SARS-CoV-2. The trial will compare two different experimental medication arms to the control arm comprising the use of standard personal protective equipment (PPE) with no additional pharmacological intervention.

Timeline

Start
2020-12-08
Primary completion
2022-02-28
Completion
2022-02-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Daclatasvir Small molecule 60 mg
Comparator Nitazoxanide Other / unclassified 1000 mg
Comparator Sofosbuvir Small molecule 400 mg

Indications